Christopher R. Fenimore, SVP Finance & CFO at REGENERON PHARMACEUTICALS, INC. (REGN), sold 8,138 shares at $953.47 ($7.8M) on 2024-02-09, disclosed to the SEC on 2024-02-12.
Open-market sale of $7.8M REGN by SVP Finance & CFO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $950.49 | 344 | $327K | 4.2% |
| 2 | $950.49 | 344 | $327K | 4.2% |
| 3 | $951.39 | 487 | $463K | 6.0% |
| 4 | $951.39 | 487 | $463K | 6.0% |
| 5 | $952.62 | 1,046 | $996K | 12.8% |
| 6 | $952.62 | 1,046 |
| $996K |
| 12.8% |
| 7 | $953.47 | 1,342 | $1.3M | 16.5% |
| 8 | $953.47 | 1,342 | $1.3M | 16.5% |
| 9 | $954.57 | 1,100 | $1.1M | 13.5% |
| 10 | $955.00 | 600 | $573K | 7.4% |
| Total | $953.01 avg | 8,138 | $7.8M | 100% |
| Filing → |
| REGN | SELL | 2023-12-26 | $3.3M | — | Filing → |
| REGN | SELL | 2023-03-27 | $3.5M | — | Filing → |
| REGN | SELL | 2022-10-07 | $1.4M | — | Filing → |